Immunovant (IMVT)
(Real Time Quote from BATS)
$29.31 USD
-0.27 (-0.91%)
Updated May 8, 2024 11:44 AM ET
2-Buy of 5 2
C Value D Growth D Momentum D VGM
Brokerage Reports
Immunovant, Inc. [IMVT]
Reports for Purchase
Showing records 1 - 20 ( 100 total )
Company: Immunovant, Inc.
Industry: Medical - Biomedical and Genetics
Company: Immunovant, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Immunovant, Inc.
Industry: Medical - Biomedical and Genetics
Company: Immunovant, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Immunovant, Inc.
Industry: Medical - Biomedical and Genetics
Long Overlooked, GravesÂ’ Disease Goes In Vogue With New Approaches
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Immunovant, Inc.
Industry: Medical - Biomedical and Genetics
Company: Immunovant, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Immunovant, Inc.
Industry: Medical - Biomedical and Genetics
Pedal to the Metal for Immunovant as It Looks to Keep Pace with Competitors in FcRn Space; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Immunovant, Inc.
Industry: Medical - Biomedical and Genetics
Company: Immunovant, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Immunovant, Inc.
Industry: Medical - Biomedical and Genetics
Initial Data in Grave''s Disease Gives Immunovant an Indication to Itself; Target to $51
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Immunovant, Inc.
Industry: Medical - Biomedical and Genetics
Company: Immunovant, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Immunovant, Inc.
Industry: Medical - Biomedical and Genetics
Company: Immunovant, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Immunovant, Inc.
Industry: Medical - Biomedical and Genetics
''1402 Confirms Profile and Ready to Move into the Clinic; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Immunovant, Inc.
Industry: Medical - Biomedical and Genetics
Company: Immunovant, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Immunovant, Inc.
Industry: Medical - Biomedical and Genetics
Optimized Entry and Exit Levels for IMVT 112123
Provider: Stock Traders Daily
Analyst: Research Department
Company: Immunovant, Inc.
Industry: Medical - Biomedical and Genetics
With SAD and Early MAD Data in the Bank, Eyes Turn to Final Phase 1 MAD Readout; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D